Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · P&G HYGIENE & HEALTH CARE · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
P&G HYGIENE & HEALTH CARE
NSE: PGHH · BSE: 500459
Fast Moving Consumer Goods › Fast Moving Consumer Goods › Personal Products › Personal Care

P&G HYGIENE & HEALTH CARE

StateQ1 FY27 filed
Last close · 27 Oct 2026₹6,809.00
Market cap₹22.1k cr
TTM P/E · P/B · EV/EBITDA27.9 · 29.33 · 19.3

Sells personal care products in India across two flagship brand families: feminine hygiene (Whisper) and health care (Vicks). Whisper leads India's feminine care category with nearly half the market, selling sanitary pads and period pants to women; the femcare category itself still has sub-50% consumer penetration, which management flags as a runway. Vicks holds more than 50% share in India's Cough & Cold category, selling products such as VapoRub, Cough Syrup, Steam Pods, Double Power drops and ZzzQuil sleep supplements to households. Distribution reach expanded by 1 million stores over three years, with e-commerce and quick commerce (including a Zepto co-creation for Whisper Period Pants) cited as key growth channels. The cost stack is dominated by other operating expenses at 31.2% of revenue and materials at 17.2%, with a productivity programme delivering Rs 93 cr of savings in FY25 and Rs 86 cr in FY26, fully reinvested into brand and product superiority. FY26 revenue stood at Rs 4,290.42 cr with an EBITDA margin of 28.28%. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Feminine Hygiene (Whisper), Personal Healthcare (Vicks). Asset-light, brand-led personal care FMCG built around two category-leading franchises.

What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.

Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)

₹ crore · standaloneFY22FY23FY24FY25FY26
Revenue3,1253,0653,2743,3744,290
EBITDA (ex other income)7636548528711,171
margin %24.421.326.025.827.3
Owners' profit533527594637857
EPS, as reported (₹)164.26162.32182.98196.11263.86
ROE % · ROCE %— · —— · —— · —86.4 · 102.7113.7 · 135.4
Debt / equity (x)———0.000.00
Cash from operations———593924
Capex———(55)0
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · P&G HYGIENE & HEALTH CARE · 28 October 2026Page 2 of 3

Exhibit 2: Quarterly performance, last 8 quarters

₹ croreQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,1351,2489929371,1501,262941891
Profit before tax285364213265282402218170
Net profit212269156192210301153126
EPS (₹)65.2882.7448.0959.1764.6592.8747.1738.90
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.

Exhibit 3: Peers — basic industry group, by market cap

CompanyM.cap ₹ crP/EP/BEV/EBITDAROE %ROCE %Rev CAGR 5y %EBITDA m. %
GODREJ CONSUMER PRODUCTS84,80344.36.7027.614.719.06.619.8
DABUR INDIA LTD63,47432.25.3821.215.819.86.624.3
COLGATE PALMOLIVE LTD.43,61232.427.53—83.7107.1—31.3
CUPID LIMITED42,491116.294.26281.824.030.3—40.3
GILLETTE INDIA LTD23,82335.725.17—69.183.4—29.8
P&G HYGIENE & HEALTH CARE ◆22,10227.929.33—113.7134.4—20.1
EMAMI LIMITED16,06121.45.5015.426.528.45.623.5
HONASA CONSUMER LIMITED14,62150.410.3646.014.216.9—17.6
Source: exchange data and filed statements via the screener; multiples at current prices.

Exhibit 4: Where the company sits in its group

MetricCompanyGroup medianRankBetter than
P/E (TTM)27.935.75 of 1571%
P/B29.36.712 of 138%
ROCE134.419.41 of 16100%
ROE113.715.81 of 13100%
Debt / Equity0.00.01 of 1350%
EBITDA margin20.123.58 of 1342%
Revenue growth(4.9)13.411 of 1423%
Profit growth(34.3)9.411 of 1317%
Market cap2210298356 of 1667%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · P&G HYGIENE & HEALTH CARE · 28 October 2026Page 3 of 3

Exhibit 5: Filings of the last 90 days, with the measured price reaction

Date · filingCategoryImportanceNext day %5-day %
7 Oct 2026 · Submission of SEBI Regulation 74(5) Certificate for Q2 FY27complianceminimal——
25 Sept 2026 · Trading Window Closure Ahead of Q2 Resultscomplianceminimal——
25 Sept 2026 · Flavia Machado appointed as Company Secretary, effective Sep 29, 2026management changesmedium——
23 Sept 2026 · P&G Hygiene denies delisting and shutdown rumoursgeneralhigh——
18 Sept 2026 · Special window reopens for re-lodging physical share transfer requestscomplianceminimal——
9 Sept 2026 · P&G HH: Shareholders approve Srividya Srinivasan as Whole-time Directormanagement changesmedium——
9 Sept 2026 · P&G Hygiene 62nd AGM: All 6 resolutions passed, dividend confirmedboard shareholder meetingsmedium——
8 Sept 2026 · P&G Hygiene & Health Care holds 62nd AGM on Sep 8, 2026board shareholder meetingslow——
17 Aug 2026 · P&G Hygiene Annual Report FY26: Revenue Rs 4290cr, PAT Rs 857crboard shareholder meetingsmedium——
17 Aug 2026 · P&G Hygiene files BRSR for FY26; turnover Rs 4,290 Cr, no material penaltiescompliancelow——
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).

How to read this document

Where a broker report showsThis document showsWhy
A rating (BUY / ADD / REDUCE / SELL)A state: the latest filed quarter and the measured reactionsan event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upsideThe current price and the multiples against the groupa target is a forecast; a multiple is a measurement
Estimate years marked EMore audited years; no estimatesMarketPing publishes no forecasts — your own model lives on the Models page

Sources, method and disclosures

This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.

Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in